biuro@scopefluidics.com +48 22 376 21 14

About
Team
Our offer
Knowledge base
News
Investor relations
Career
Contact

biuro@scopefluidics.com +48 22 376 21 14

About
Team
Our offer
Knowledge base
News
Investor relations
Career
Contact

biuro@scopefluidics.com +48 22 376 21 14

RAPORT ESPI 8/2024 | 21-06-2024 | Zakwalifikowanie projektu DSC001 do rozwoju w ramach spółki celowej

Previous PostRAPORT ESPI 7/2024 | 04-06-2024 | Informacja o warunkowej decyzji Urzędu Patentów i Znaków Towarowych Stanów Zjednoczonych o przyznaniu patentu w ramach projektu BACTEROMICOMICNext PostRAPORT ESPI 9/2024 | 25-06-2024 | Treść uchwał podjętych przez ZWZ Spółki w dniu 25 czerwca 2024 r.

0Shares

Related Posts

Edocera develops device prototype and confirms its ability to detect signs of stroke

SCOPE FLUIDICS0

Scope Fluidics after the first half of 2026: strong cash position, IVDR certification and expanding cooperation with distributors

SCOPE FLUIDICS0

Hybolic signs PARP funding agreement to develop a system for measuring insulin and glucose concentrations

SCOPE FLUIDICS0

CONTACT US

Tel. +48 22 376 21 14
Email: biuro@scopefluidics.com

Address

Ogrodowa 58
9th floor
00-876 Warsaw

KRS: 0000668408

NIP: 527-264-59-89

REGON: 142-754-170

LEI: 259400EUNFX4E2BEHU15

Company registered in the District Court for the Capital City of Warsaw in Warsaw, XII Commercial Division of the National Court Register.

Share capital: PLN 316 827,10 fully paid up

Bank Account Number: 03 2490 0005 0000 4520 3046 2136

Terms of use

Cookies Policy

Information clause

Whistleblower Protection

Scope Fluidics 2021 ® All rights reserved